机构:[1]Tianjin Medical University General Hospital, Departments of Neurology and Radiology, Tianjin Neurological Institute, Tianjin, China, the People's Republic[2]Capital Medical University, Beijing Tiantan Hospital, National Clinical Research Center for Neurological Diseases of China, Center for Neuroinflammation, Beijing, China, the People's Republic重点科室诊疗科室神经病学中心首都医科大学附属天坛医院[3]First Hospital of Shanxi Medical University, Department of Neurology, Taiyuan, China, the People's Republic[4]Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, United States
第一作者机构:[1]Tianjin Medical University General Hospital, Departments of Neurology and Radiology, Tianjin Neurological Institute, Tianjin, China, the People's Republic[2]Capital Medical University, Beijing Tiantan Hospital, National Clinical Research Center for Neurological Diseases of China, Center for Neuroinflammation, Beijing, China, the People's Republic
推荐引用方式(GB/T 7714):
Zhang C.,Yang C.,Zhang M.,et al.Comparative evaluation of modified-dose of rituximab and other initial treatment choices for Myasthenia Gravis[J].EUROPEAN JOURNAL OF IMMUNOLOGY.2019,49:1444-1444.
APA:
Zhang, C.,Yang, C.,Zhang, M.,Jia, D.,Yuan, M....&Shi, F. -D.(2019).Comparative evaluation of modified-dose of rituximab and other initial treatment choices for Myasthenia Gravis.EUROPEAN JOURNAL OF IMMUNOLOGY,49,
MLA:
Zhang, C.,et al."Comparative evaluation of modified-dose of rituximab and other initial treatment choices for Myasthenia Gravis".EUROPEAN JOURNAL OF IMMUNOLOGY 49.(2019):1444-1444